The Assay of Factor VIII: C in Heparinized Plasma: A Polybrene Neutralization Method

Summary

Factor VIII coagulant activity (VIII: C) has been shown by several investigators to exhibit increased stability in vitro when physiological levels of plasma ionized calcium are maintained by anticoagulation with heparin rather than citrate. An increase in initial activity of VIII: C in heparin over that of VIII: C in citrate has been reported but this has not been confirmed. In order to assay VIII :C in heparinized plasma, the heparin anticoagulant effect must be excluded without interfering with the validity of the assay. A one-stage clotting assay for VIII: C has been developed where heparin is neutralized by Polybrene^®, a synthetic polymerized quaternary ammonium salt. VIII :C may be accurately measured by this method which satisfies the requirements for a valid assay of parallelism and linearity.

Key words

VIII:C assay - Heparin neutralization in vitro - Polybrene

• References

• 1 Rock GA, Cruickshank WH, Tackaberry ES, Palmer DS. Improved yields of factor VIII from heparinized plasma. Vox Sang 1979; 36: 294-300
• 2 Krachmalnicoff A, Thomas DP. The stability of factor VIII in heparinized plasma. Thromb Haemostas 1983; 49: 224-227
• 3 Mikaélsson ME, Forsman N, Oswaldsson U. Human blood factor VIII: a calcium-linked protein complex. Blood 1983; 62: 1006-1015
• 4 Fabian I, Aronson M. Poly cations as possible substitutes for protamine in heparin neutralization. Thromb Res 1980; 17: 239-247
• 5 Perkash K. A comparison of the quantitative action of protamine and heparin on blood coagulation. Am J Clin Pathol 1980; 73: 676-681
• 6 Godal HC. A comparison of two heparin-neutralizing agents: protamine and polybrene. Scand J Clin Lab Invest 1960; 12: 446-457
• 7 Jaques LB, Kavanagh LW. Protamine neutralization factors for heparin. Can J Pharm Sci 1977; 12: 44-47
• 8 Cumming AM, Jones GR, Wensley RT, Cundall RB. In vitro neutralization of heparin in plasma prior to the activated partial thromboplastin time test: an assessment of four heparin antagonists and two anion exchange resins. Thromb Res 1986: 41 (in press)
• 9 Cowan JF, Khan MB, Vargo J, Joist JH. An improved method for evaluation of blood coagulation in heparinized blood. Am J Clin Pathol 1981; 75: 60-64
• 10 Hoffman JJ M L, Meulendijk PN. Evaluation of a heparin neutralizer. Thromb Res 1980; 18: 897-900
• 11 Israels ED. Partial thromboplastin time in the presence of heparin. A rapid polybrene neutralization method. Am J Clin Pathol 1982; 77: 321-324
• 12 Lämmle B, Tran TH, Duckert F. Assay of factor XII clotting activity in heparinized plasma. Am J Clin Pathol 1983; 80: 474-477
• 13 Barrowcliffe TW, Gray E. Studies of phospholipid reagents used in coagulation I: Some general properties and their sensitivity to factor VIII. Thromb Haemostas 1981; 46: 629-633
• 14 Barrowcliffe TW, Gray E. Studies of phospholipid reagents used in coagulation II: Factors influencing their sensitivity to heparin. Thromb Haemostas 1981; 46: 634-637
• 15 Hardisty RM, MacPherson JC. A one-stage factor VIII (anti-haemophilic globulin) assay and its use on venous and capillary plasma. Thrombos Diathes Haemorrh 1962; 7: 215-229
• 16 Kirkwood TB L, Snape TJ. Biometric principles in clotting and clot lysis assays. Clin Lab Haematol 1980; 2: 155-167